Markets:

Overview

News

Currencies

International

Treasuries

Skye Bioscience, Inc. - Common Stock (NQ:SKYE)

0.8782 +0.1285 (+17.14%)

Streaming Delayed Price Updated: 4:00 PM EST, Jan 2, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about Skye Bioscience, Inc. - Common Stock

< Previous 1 2 Next >

Which stocks are moving after the closing bell on Tuesday? ↗

December 23, 2025

After the conclusion of the US market's regular session on Tuesday, let's examine the after-hours session and unveil the notable performers among the top gainers and losers.

Via Chartmill

What One Fund's Sale of Centessa Stock Signals About the Fast-Rising Biotech Company ↗

November 29, 2025

Here's why a fast-rising pharmaceutical trimmed—and not abandoned—by a specialist fund signals ongoing conviction in the stock.

Via The Motley Fool

Topics Regulatory Compliance

5AM Venture Just Dumped Its Viking Stake—Smart Call or Missed Opportunity? ↗

November 18, 2025

One major biotech investor just walked away from Viking Therapeutics. Here’s what the move may—and may not—mean for the company’s clinical-stage future.

Via The Motley Fool

Topics Regulatory Compliance

Earnings Scheduled For November 10, 2025 ↗

November 10, 2025

Via Benzinga

Earnings Scheduled For August 7, 2025 ↗

August 07, 2025

Via Benzinga

Earnings Scheduled For May 8, 2025 ↗

May 08, 2025

Via Benzinga

5AM Venture Bails on MoonLake After a Brutal Year: Here’s What Stands Out ↗

November 18, 2025

A major biotech investor just walked away from MoonLake after a rough year for the stock. Here’s what that move signals—and what long-term investors should keep an eye on next.

Via The Motley Fool

Insights Ahead: Skye Bioscience's Quarterly Earnings ↗

November 07, 2025

Via Benzinga

The Weight-Loss Drugs Craze Is Going Strong. But Stock Investors Should Know A Few Things. ↗

November 07, 2025

The feast that saw obesity-tied stocks skyrocket in 2024 is over. Investors' appetite for weight-loss drugs has waned.

Via Investor's Business Daily

Topics Government

These stocks are moving in today's session ↗

October 06, 2025

Here are the top movers in Monday's session, showcasing the stocks with significant price changes.

Via Chartmill

Nasdaq Jumps Over 150 Points; Skye Bioscience Shares Plunge ↗

October 06, 2025

Via Benzinga

12 Health Care Stocks Moving In Monday's Intraday Session ↗

October 06, 2025

Via Benzinga

Let's take a look at the stocks that are in motion in today's session. ↗

October 06, 2025

Wondering how the US markets performed in the middle of the day on Monday? Discover the movers and shakers of today's session in our comprehensive analysis.

Via Chartmill

US Stocks Mixed; Dow Falls 100 Points ↗

October 06, 2025

Via Benzinga

Topics Stocks

Skye Bioscience's Investigational Drug Disappoints As Monotherapy For Weight Loss ↗

October 06, 2025

Skye Bioscience'a trial showed nimacimab alone missed goals, while a combo with Novo Nordisk's drug delivered stronger weight loss results.

Via Benzinga

Monday's session: gap up and gap down stocks ↗

October 06, 2025

The session on Monday is off to an intriguing start with several stocks showing significant price gaps. Let's examine the gap up and gap down stocks in today's session.

Via Chartmill

Why AMD Shares Are Trading Higher By Over 34%; Here Are 20 Stocks Moving Premarket ↗

October 06, 2025

Via Benzinga

Wondering what's happening in today's pre-market session? ↗

October 06, 2025

Discover the top movers in Monday's pre-market session and stay informed about market dynamics.

Via Chartmill

12 Health Care Stocks Moving In Monday's Pre-Market Session ↗

October 06, 2025

Via Benzinga

12 Health Care Stocks Moving In Friday's After-Market Session ↗

September 26, 2025

Gainers Enanta Pharma (NASDAQ: ENTA) stock rose 15.6% to $9.13 during Friday's after-market session. The market value of their outstanding shares is at $165.6 million.

Via Benzinga

Could This New Drug Be The Safer Way To Fight Obesity? ↗

September 19, 2025

Skye Bioscience reported favorable Phase 1b nimacimab results, with analysts citing strong potential in obesity alongside GLP-1 therapies.

Via Benzinga

Skye Bioscience Advances Position In Competitive Obesity Market With Promising Data ↗

September 05, 2025

Skye Bioscience's latest data show nimacimab boosted tirzepatide's weight loss effects and reduced obesity treatment rebound risk.

Via Benzinga

Skye (SKYE) Q2 R&D Soars 249% No Revenue ↗

August 07, 2025

Via The Motley Fool

Topics Intellectual Property

In today's session, these stocks are experiencing unusual volume. ↗

June 24, 2025

Which stocks have an unusual volume on Tuesday?

Via Chartmill

What's going on in today's session ↗

June 23, 2025

Curious about what's happening in today's session? Check out the latest stock movements and price changes.

Via Chartmill

12 Health Care Stocks Moving In Monday's Intraday Session ↗

June 23, 2025

Via Benzinga

Which stocks are experiencing notable movement on Monday? ↗

June 23, 2025

Stay up-to-date with the latest market trends in the middle of the day on Monday. Explore the top gainers and losers during today's session in our detailed report.

Via Chartmill

These stocks are moving in today's pre-market session ↗

June 23, 2025

Discover the top movers in Monday's pre-market session and stay informed about market dynamics.

Via Chartmill

Small Cap News Movers: Your Daily Digest of Stocks Making Moves on Market News ↗

April 15, 2025

Via Stocktwits

Topics Animal Testing Artificial Intelligence Stocks

Top stock movements in today's session. ↗

April 15, 2025

Here are the top movers in Tuesday's session, showcasing the stocks with significant price changes.

Via Chartmill

< Previous 1 2 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.